Background: An individual's genetic fingerprint is emerging as a pivotal predictor of numerous disease‐ and treatment‐related factors. Single nucleotide polymorphisms (SNPs) in drug‐metabolizing enzymes play key roles in an individual's exposure to a malignancy‐associated risk, such as Aflatoxin B1 (AFB1)‐induced hepatocellular carcinoma (HCC). Aim: This study aimed at reviewing literature on the polymorphisms that exist in CYP enzymes and their possible link with susceptibility to AFB1‐induced HCC. Materials & Methods: A set of keywords associated with the study subject of interest was used to search the Google Scholar and the PubMed database. The last ten years' worth of research projects were included in the results filter. The research involved HCC patients and any connection between polymorphic forms of CYP enzymes and their susceptibility to AFB1‐induced HCC, including older but significant data. Results: Variations in CYP1A2 and CYP3A4 were reported to impact the rate and magnitude of AFB1 bio‐activation, thus influencing an individual's vulnerability to develop HCC. In HCC patients, the activity of CYP isoforms varies, where increased activity has been reported with CYP2C9, CYP2D6, and CYP2E1, while CYP1A2, CYP2C8, and CYP2C19 exhibit decreased activity. CYP2D6*10 frequency has been discovered to differ considerably in HCC patients. Rs2740574 (an upstream polymorphism in CYP3A4 as detected in CYP3A4*1B) and rs776746 (which affects CYP3A5 RNA splicing), both of which influence CYP3A expression, thus impacting the variability of AFB1‐epoxide adducts in HCC patients. Discussion: CYP1A2 is the primary enzyme accountable for the formation of harmful AFBO globally. CYP3A4, CYP3A5, CYP3A7, CYP2B7, and CYP3A3 are also implicated in the bio‐activation of AFB1 to mutagenic metabolites. It is thought that CYP3A4 is the protein that interacts with AFB1 metabolism the most. Conclusion: Polymorphic variants of CYP enzymes have a functional impact on the susceptibility to AFB1‐induced HCC. Outlining such variation and their implications may provide deeper insights into approaching HCC in a more personalized manner for guiding future risk‐assessment, diagnosis, and treatment. [ABSTRACT FROM AUTHOR]